Corvidane
Early Stage
Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants from NASH
Overview
Raised: $371,284
Total Commitments ($USD)
Platform
Wefunder
Start Date
01/04/2022
Close Date
04/30/2022
Min. Goal
$50,000
Max. Goal
$1,000,000
Min. Investment
$100
Security Type
SAFE
Series
Pre-Seed
SEC Filing Type
RegCF
Early Bird Val. Cap
$19,000,000
Valuation Cap
$20,000,000
Discount
10%
Rolling Commitments ($USD)
Status
Funded
Reporting Date
05/01/2022
Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise
$3,201
# of Investors
229
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2014
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B/B2C
Margin
Medium
Capital Intensity
High
Corvidane, with a valuation of $20 million, is raising funds on Wefunder. The company is developing a novel drug to prevent heart attacks, strokes, and liver transplants from NASH. The drug Corvida is an innovative approach to treating heart and liver diseases and is built on strong preclinical science. It is safe, contains Omega-7 and Omega-9, and works by improving lipid metabolism. Paresh Soni and Damion Boyer founded Corvidane in July 2014. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $1,000,000. The campaign proceeds will be used for operations, toxicology study, market research, and manufacturing.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-33,665 |
$-39,724 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$2,738 |
$12,851 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$69,379 |
$67,875 |
|
Short-Term Debt |
$80,607 |
$64,755 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$80,607 |
$64,755 |
Financials as of: 01/04/2022
Create a free account today to gain access to KingsCrowd analytics.
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Already a member? Log in here.
Ratings 
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.